- Home
- HRTX vs CMPX Comparison
HRTX vs CMPX Comparison
Compare HRTX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- CMPX
- Stock Information
- Founded
- HRTX 1983
- CMPX 2014
- Country
- HRTX United States
- CMPX United States
- Employees
- HRTX N/A
- CMPX N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- CMPX Health Care
- Exchange
- HRTX Nasdaq
- CMPX Nasdaq
- Market Cap
- HRTX 270.7M
- CMPX 229.5M
- IPO Year
- HRTX 1987
- CMPX N/A
- Fundamental
- Price
- HRTX $1.84
- CMPX $1.75
- Analyst Decision
- HRTX Strong Buy
- CMPX Strong Buy
- Analyst Count
- HRTX 3
- CMPX 8
- Target Price
- HRTX $5.67
- CMPX $13.38
- AVG Volume (30 Days)
- HRTX 1.1M
- CMPX 2.8M
- Earning Date
- HRTX 05-06-2025
- CMPX 05-12-2025
- Dividend Yield
- HRTX N/A
- CMPX N/A
- EPS Growth
- HRTX N/A
- CMPX N/A
- EPS
- HRTX N/A
- CMPX N/A
- Revenue
- HRTX $144,285,000.00
- CMPX $850,000.00
- Revenue This Year
- HRTX $11.81
- CMPX $47.65
- Revenue Next Year
- HRTX $15.79
- CMPX $2,767.57
- P/E Ratio
- HRTX N/A
- CMPX N/A
- Revenue Growth
- HRTX 13.57
- CMPX N/A
- 52 Week Low
- HRTX $1.04
- CMPX $0.77
- 52 Week High
- HRTX $3.93
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- HRTX 39.27
- CMPX 41.42
- Support Level
- HRTX $1.65
- CMPX $1.60
- Resistance Level
- HRTX $2.00
- CMPX $1.78
- Average True Range (ATR)
- HRTX 0.14
- CMPX 0.27
- MACD
- HRTX -0.03
- CMPX 0.03
- Stochastic Oscillator
- HRTX 30.16
- CMPX 38.01
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.